Moderna 2022 Priorities and Capital Allocation
Moderna's Therapeutics (Pipeline 3/3)
ID #
Preclinical
development
Phase 1
Phase 2
Phase 3
Commercial
Moderna rights
Modality
Program
IL-2
mRNA-6231
Systemic
Autoimmune disorders
secreted & cell Relaxin
mRNA-0184
surface
Heart failure
therapeutics
PD-L1
mRNA-6981
Autoimmune hepatitis
Personalized cancer vaccine
mRNA-4157
(PCV)
Cancer
ā0000
vaccines
KRAS vaccine
mRNA-4671
Checkpoint vaccine
mRNA-4359
Intratumoral
OX40L/IL-23/IL-36y (Triplet)
Immuno-
mRNA-2752
Solid tumors/lymphoma
oncology
IL-12
MEDI1191
Solid tumors
Localized
VEGF-A
Regenerative
AZD8601
Myocardial ischemia
Therapeutics
Propionic acidemia (PA)
mRNA-3927
Slide 42
Methylmalonic acidemia (MMA) mRNA-3705
Systemic
Intracellular
Glycogen storage disease type
la (GSD1a)
mRNA-3745
Open IND
Therapeutics
Phenylketonuria (PKU)
mRNA-3283
Crigler-Najjar syndrome type 1
Inhaled
mRNA-3351
(CN-1)
Pulmonary
Therapeutics
Cystic fibrosis (CF)
VXC-522
Worldwide
Worldwide
Worldwide
50-50 global profit
sharing with Merck
Worldwide
Worldwide
Worldwide
50-50 U.S. profit sharing;
AZ to pay royalties on ex-
U.S. sales
AZ to pay milestones and
royalties
Worldwide
Worldwide
Worldwide
Worldwide
Provided to ILCM free of
charge
Vertex to pay milestones
and royalties
modernaView entire presentation